This review published raises concerns about the potential cancer risks of the N1-methyl-pseudouridine (m1-psi) modification used in COVID-19 mRNA vaccines. Researchers found that this modification, which prevents mRNA degradation and enhances protein production, also suppresses the immune response. This modification could potentially create an environment conducive to cancer development. Additionally, a study cited in the review, including one on mice with melanoma, showed a stronger immune response and better survival rates with natural mRNA than modified mRNA. The authors call for future mRNA therapeutics to use lower percentages of modified RNA to avoid these risks.

Editor’s note: While the modification ensures some effectiveness, its broader implications for immune system functionality cannot be overlooked. The evidence suggests potentially promoting cancer in susceptible individuals. This calls for a reevaluation of the mRNA vaccine composition. There should be a balance between efficacy and safety, especially for immunocompromised people.

Read Original Article